FDA grants Orphan Drug Designation (ODD) for NTZ for ACLF, a severe condition with no approved therapiesNTZ is being advanced in ACLF through its G1090N reformulation, designed to unlock its clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results